Top Page
Recordati Industria Chimica e Farmaceutica SPA
(LSE:REC)
Recordati Industria Chimica e Farmaceutica SPA (REC) vs. iShares MSCI Italy ETF (EWI)
Recordati Industria Chimica e Farmaceutica SPA Business Overview & Revenue Model
Recordati Industria Chimica e Farmaceutica SPA Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.34B | 2.08B | 1.85B | 1.58B | 1.45B |
| Gross Profit | 1.60B | 1.42B | 1.29B | 1.15B | 1.04B |
| EBITDA | 795.37M | 708.16M | 559.35M | 578.35M | 566.83M |
| Net Income | 416.51M | 389.21M | 312.34M | 385.97M | 354.98M |
Balance Sheet | |||||
| Total Assets | 5.13B | 4.21B | 4.00B | 2.82B | 2.71B |
| Cash, Cash Equivalents and Short-Term Investments | 322.42M | 221.81M | 284.73M | 244.58M | 188.23M |
| Total Debt | 22.84M | 1.81B | 1.72B | 992.19M | 1.06B |
| Total Liabilities | 3.26B | 2.52B | 2.45B | 1.43B | 1.44B |
| Stockholders Equity | 1.88B | 1.69B | 1.55B | 1.38B | 1.28B |
Cash Flow | |||||
| Free Cash Flow | 535.10M | 102.06M | 365.35M | 404.29M | 271.90M |
| Operating Cash Flow | 569.92M | 485.32M | 461.69M | 491.65M | 403.57M |
| Investing Cash Flow | -844.94M | -379.62M | -767.12M | -87.50M | -131.56M |
| Financing Cash Flow | 372.11M | -168.91M | 341.28M | -355.94M | -264.29M |
Recordati Industria Chimica e Farmaceutica SPA Technical Analysis
Recordati Industria Chimica e Farmaceutica SPA Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €11.15B | 26.67 | 22.02% | 2.37% | 12.85% | 7.34% | |
66 Neutral | €444.84M | 26.90 | 2.18% | 17.78% | 63.72% | ||
65 Neutral | €655.04M | 19.93 | 39.51% | ― | 219.91% | ― | |
65 Neutral | €4.95B | 26.88 | 11.27% | 1.33% | 3.24% | 17.49% | |
52 Neutral | $7.63B | 0.11 | -62.96% | 2.08% | 16.16% | 0.31% |
Recordati Industria Chimica e Farmaceutica SPA Corporate Events
Recordati S.p.A. announced an update on its share buyback program, which began on 30 April 2025. The program aims to purchase shares to support stock options and performance share plans for the management of the Recordati Group. From 14 to 18 July 2025, Recordati purchased 130,231 ordinary shares at an average price of €52.9464 per share. As of 18 July 2025, the company held 3,764,910 own shares, representing 1.800% of its share capital. This move is part of Recordati’s strategy to enhance shareholder value and support its incentive plans.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has announced an update on its share buyback program, which began on April 30, 2025, following the Shareholders’ Meeting resolution. The program aims to purchase shares to support stock options and performance shares plans for the company’s management. Between July 7 and July 11, 2025, Recordati purchased 75,466 shares at an average price of 53.8449 Euros per share, bringing its total holdings to 3,674,679 shares, representing 1.757% of its share capital. This move is part of Recordati’s broader strategy to enhance its market position and incentivize its management team, potentially impacting shareholder value and market perception.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. announced an update on its share buyback program, which was initiated to support stock options and performance share plans for the company’s management. From June 30 to July 4, 2025, the company purchased 80,423 ordinary shares at an average price of €53.5657, increasing its total holdings to 3,623,213 shares, representing 1.733% of its share capital. This strategic move aims to strengthen the company’s market position and provide incentives for its management team.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati has engaged in transactions involving the sale and purchase of treasury shares. These transactions include the sale of shares to beneficiaries of stock option plans and the purchase of shares through a buy-back program executed by UBS Europe SE. This strategic move is likely aimed at optimizing capital structure and enhancing shareholder value.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the execution of its share buyback program, which was initiated to support stock options and performance share plans for the company’s management. The company purchased a total of 90,057 ordinary shares between June 23 and June 27, 2025, increasing its total holdings to 3,563,650 shares, representing 1.704% of its share capital.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated the market on its ongoing share buyback program, initiated to support its stock options and performance share plans. The company purchased 89,172 ordinary shares between June 16 and June 20, 2025, reflecting a strategic move to enhance shareholder value and support future incentive plans.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the progress of its share buyback program, which was initiated to support stock options and performance share plans for its management. Between June 9 and June 13, 2025, Recordati purchased 82,346 of its own shares, representing 1.620% of its share capital, as part of its strategy to enhance shareholder value and incentivize management.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati announced an update on its share buyback program, which began on April 30, 2025, following a resolution by the Shareholders’ Meeting. The program is intended to purchase shares for stock option and performance share plans for the company’s management. During the period from June 2 to June 6, 2025, Recordati purchased 70,709 ordinary shares, bringing its total holdings to 3,360,825 shares, representing 1.607% of its share capital.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated on its share buyback program initiated in April 2025, aimed at acquiring shares for stock option and performance share plans for management. Between May 26 and May 30, 2025, Recordati purchased 76,378 shares, holding 1.604% of its share capital by the end of May, reflecting its strategic focus on incentivizing management and aligning with shareholder interests.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR55.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has announced an update on its share buyback program initiated on April 30, 2025. The company purchased 89,225 shares between May 19 and May 23, 2025, at an average price of 51.3752 Euros per share. This buyback is part of Recordati’s strategy to allocate shares for stock option and performance share plans for its management, reflecting its commitment to incentivizing its leadership and enhancing shareholder value.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the progress of its share buyback program, initiated on April 30, 2025. The program, which aims to purchase shares for stock option and performance share plans, saw the acquisition of 88,677 ordinary shares between May 12 and May 16, 2025, reflecting the company’s strategic focus on incentivizing management and aligning with future incentive plans.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its stakeholders on the execution of its share buyback program, which was initiated on April 30, 2025. The program aims to purchase shares to support stock options and performance share plans for the management of the Recordati Group. As of May 9, 2025, Recordati has purchased 2,329 ordinary shares at a weighted average price of €52.5512 each, and now holds 3,136,086 own shares, representing 1.500% of its share capital. This strategic move is expected to enhance the company’s incentive plans and align management interests with those of shareholders.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati has reported strong financial performance in the first quarter of 2025, with consolidated net revenues increasing by 11.9% to €680.0 million. The company’s growth is driven by robust performance in its Specialty & Primary Care and Rare Diseases segments, with significant contributions from the extension of Isturisa’s indication and the approval of Signifor LAR in China. The company maintains its financial targets for 2025 and anticipates continued momentum through 2027, supported by strategic growth initiatives and disciplined cost management.
Recordati S.p.A. has updated its shareholders on the execution of its share buyback program, initiated on April 30, 2025, following a resolution from the Shareholders’ Meeting. The program aims to purchase shares to service stock options and performance share plans for the company’s management. As of May 2, 2025, Recordati has acquired 3,103 shares, bringing its total to 3,133,757 own shares, which is 1.499% of its share capital. This strategic move is part of Recordati’s broader efforts to enhance shareholder value and support its incentive plans.
Recordati has released the summary report of the voting results from its Ordinary Shareholders’ Meeting held on April 29, 2025. This report is accessible on the company’s website and through an authorized storage mechanism, reflecting the company’s commitment to transparency and shareholder engagement.
Recordati S.p.A. has announced a program to purchase up to 2,000,000 of its own shares to support stock option and performance share plans for its management. The program, managed by UBS Europe SE, will run until November 7, 2025, with a maximum countervalue of €125 million, aiming to enhance management incentives and potentially impact the company’s market positioning.
Recordati S.p.A. announced the approval of its 2024 financial statements and a dividend increase to €1.27 per share, reflecting a 5.8% rise from the previous year. Additionally, a new Board of Directors was appointed for the 2025-2027 period, with Andrea Recordati and Robert Koremans confirmed as Chairman and CEO, respectively. The company also renewed its authorization to purchase and dispose of treasury shares and approved a new share purchase program to support stock option and performance share plans.